Načítá se...
Association of concurrent acid-suppression therapy with survival outcomes and adverse event incidence in oncology patients receiving erlotinib
PURPOSE: Acid-suppression therapy is known to decrease the systemic exposure of erlotinib. The erlotinib prescribing information also recommends staggering dosing with a histamine-2 receptor antagonist (H(2)RA) and avoiding concurrent use of a proton-pump inhibitor (PPI). This retrospective analysis...
Uloženo v:
| Vydáno v: | Cancer Chemother Pharmacol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4967016/ https://ncbi.nlm.nih.gov/pubmed/27372908 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-016-3087-6 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|